Zydus Lifesciences Ltd.

Cadila Healthcare has declared the first day launch of Zolmitriptan orally disintegrating tablets upon receiving the final approval from the US Food and Drug Administrator (USFDA). The drug is used in the treatment of migraine, has an estimated sale of $175 million in 2012 as per IMS.

The company would market the product in the strengths of 2.5 mg and 5mg in the US market. The group now has 79 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.

The flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.